February 2014 Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
PLEASE NOTE: We will meet in Mendel 154.
- Topic: "Bioanalytical Approaches for Large Molecule Quantitation in Drug Discovery"
- Speaker: Matthew Szapacs, GlaxoSmithKline
- Date: Monday, February 10, 2014. 6:00 PM
- Time: Social Hour: 6:00 PM.
Talk: 7:00 PM.
Please RSVP to John Masucci JMasucci@its.jnj.com by Thursday February 6.
- Place: Department of Chemistry, Villanova University (Room 154, Mendel Hall)
- Abstract: Traditionally, immunoassay has been used to quantitate large molecule therapeutics and biomarkers due to the relative low cost, high throughput and sensitivity associated with these assays. However, improvements in liquid chromatography tandem mass spectrometry (LC-MS/MS) equipment have lead its use to overcome some of the common challenges associated with immunoassays. In practice, leveraging the benefits of both technologies should be the preferred route to provide the best bioanalytical support throughout drug development. To accomplish this requires a thorough evaluation of the strengths and weaknesses of each technique taking into account such factors as: the stage of the therapeutic, selectivity concerns in the patient population, and reagent availability. With these factors in mind, study support could require the use of both methodologies for a single study or switching between platforms throughout the drug discovery and development process. Finally, to ensure translation and valid interpretation of data between methods and across studies requires a comprehensive and timely cross-validation strategy. This presentation will focus on case studies for the use of LC-MS/MS and/or immunocapture techniques for bioanalytical study support.
- Bio: Currently, Dr. Matthew Szapacs is a senior scientific investigator in the Bioanalytical Sciences and Toxicokinetics department in DMPK at GlaxoSmithKline. His focus is on developing and validating bioanalytical methods for biotherapeutics and biomarkers using both LC-MS/MS and immunoassay methodologies. Prior to this, he attended graduate school at The Pennsylvania State University working in Dr. Anne Andrews’ lab and wrote his dissertation on the neurochemistry of neurodegernative diseases. This was followed by a post-doctoral fellowship at Vanderbilt University in Dr. Daniel Liebler’s lab where he used LC-MS/MS technologies to study protein adduction due to oxidative stress. Over the course of his career he has published multiple papers and given various podium presentations on the use of LC-MS/MS and immunoassay for the quantitation of proteins and peptides in support of pharmacokinetic/pharmacodynamic studies. In 2010 his paper entitled ‘Absolute Quantification of a Therapeutic Domain Antibody using Ultra-Performance Liquid Chromatography Mass Spectrometry and Immunoassay.’ was selected as an editor’s choice for best paper in Bioanalysis. In addition, Dr. Szapacs has won numerous internal awards for contributions to exceptional analytical science at GlaxoSmithKline.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated 11/13/2013